Functionally active complement proteins C6 and C7 detected in C6- and C7-deficient individuals
- PMID: 2004484
- PMCID: PMC1535307
- DOI: 10.1111/j.1365-2249.1991.tb05656.x
Functionally active complement proteins C6 and C7 detected in C6- and C7-deficient individuals
Abstract
Two sensitive sandwich ELISAs based on monoclonal antibodies directed to native C6 and C7 allowed the detection and quantitation of these complement proteins in 20 out of 37 serum samples from individuals who had previously been classified as deficient in these proteins as assessed by immunochemical and/or functional assays. Furthermore, serum from four C6-deficient and one combined C6-/C7-deficient individual showed an increase in the terminal complement complex (TCC) and a decrease in native C6 and C7 after complement activation as assayed by specific ELISAs. Despite their (incomplete) deficiencies, these individuals therefore possess functionally active terminal complement proteins with respect to their ability to generate the TCC. As these individuals have no history of a susceptibility to neisserial infections, even low concentrations of functionally active C6 and C7 may provide sufficient protection against those micro-organisms whose destruction requires TCC formation.
Similar articles
-
[C6, C7, C8 and C9].Nihon Rinsho. 2010 Jun;68 Suppl 6:90-3. Nihon Rinsho. 2010. PMID: 20942009 Japanese. No abstract available.
-
[Immunologic tests: C6, C7, C8 and C9].Nihon Rinsho. 2005 Jul;63 Suppl 7:92-4. Nihon Rinsho. 2005. PMID: 16111197 Review. Japanese. No abstract available.
-
[Clinical significance of C6, C7, C9 and C1-INH analysis].Nihon Rinsho. 1990 Feb;48 Suppl:662-5. Nihon Rinsho. 1990. PMID: 2113138 Japanese. No abstract available.
-
Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies.Complement Inflamm. 1991;8(5-6):328-40. doi: 10.1159/000463204. Complement Inflamm. 1991. PMID: 1724954
-
[C6, C7, C8 and C9].Nihon Rinsho. 1999 Nov;57 Suppl:71-4. Nihon Rinsho. 1999. PMID: 10635778 Review. Japanese. No abstract available.
Cited by
-
Development of an anti-human complement C6 monoclonal antibody that inhibits the assembly of membrane attack complexes.Blood Adv. 2020 May 12;4(9):2049-2057. doi: 10.1182/bloodadvances.2020001690. Blood Adv. 2020. PMID: 32396613 Free PMC article.
-
Properties of a low molecular weight complement component C6 found in human subjects with subtotal C6 deficiency.Immunology. 1992 Jan;75(1):10-6. Immunology. 1992. PMID: 1537585 Free PMC article.
-
Complement component C7 deficiency in two Spanish families.Immunology. 2004 Dec;113(4):518-23. doi: 10.1111/j.1365-2567.2004.01997.x. Immunology. 2004. PMID: 15554930 Free PMC article.
-
Vaccine-induced opsonophagocytic immunity to Neisseria meningitidis group B.Clin Vaccine Immunol. 2008 May;15(5):799-804. doi: 10.1128/CVI.00036-08. Epub 2008 Mar 19. Clin Vaccine Immunol. 2008. PMID: 18353918 Free PMC article.
-
Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes.Immunology. 2001 Jul;103(3):390-8. doi: 10.1046/j.1365-2567.2001.01249.x. Immunology. 2001. PMID: 11454069 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous